10:35 AM
 | 
Nov 30, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Imfinzi fails again in MYSTIC trial for first-line NSCLC

In another strike against tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the co-primary endpoint of improving overall survival (OS) in the Phase III MYSTIC trial to treat previously untreated non-small cell lung cancer.

AZ leadership had called OS a more clinically meaningful endpoint than progression-free survival (PFS) after the combo missed the PFS endpoint in 2017 (see "AZ Plummets on MYSTIC Readout in NSCLC").

Imfinzi as monotherapy also missed the OS endpoint in MYSTIC, but had a slightly...

Read the full 421 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >